Related Experiment Video

Updated: Aug 8, 2026

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction
08:02

In Vivo Augmentation of Gut-Homing Regulatory T Cell Induction

Published on: January 22, 2020

Immunostimulatory oligonucleotides inhibit colonic proinflammatory cytokine production in ulcerative colitis

Daniel Rachmilewitz1, Fanny Karmeli, Shimon Shteingart

  • 1Department of Medicine, Shaare Zedek Medical Center, Jerusalem, Israel. tamid@netvision.net.il

Inflammatory Bowel Diseases
|May 4, 2006
PubMed
Abstract

Insights

Certain Toll-like receptor-9 (TLR-9) ligands, specifically class B CpG oligonucleotides (ODNs), significantly reduce proinflammatory cytokine production in ulcerative colitis (UC) models, suggesting therapeutic potential.

Area of Science:

  • Immunology
  • Gastroenterology
  • Molecular Biology

Background:

  • Toll-like receptor-9 (TLR-9) ligands have previously demonstrated efficacy in ameliorating experimental colitis.
  • This study investigates the impact of TLR-9 ligands on the production of proinflammatory cytokines in human colonic mucosa.

Purpose of the Study:

  • To evaluate the effect of various immunostimulatory (ISS) CpG oligonucleotides (ODNs) on the generation of tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) by human colonic mucosa from patients with ulcerative colitis (UC).

Main Methods:

  • Colonoscopic biopsies were obtained from active UC patients and normal subjects.
  • Tissues were organ cultured and treated with different classes of ISS CpG ODNs.
  • TNF-alpha and IL-1beta levels were quantified using enzyme-linked immunosorbent assay.

Main Results:

  • Inflamed colonic mucosa in active UC produced significantly higher levels of TNF-alpha and IL-1beta compared to normal mucosa.
  • Class B CpG ODNs inhibited TNF-alpha and IL-1beta generation by 50%, while other classes had minimal or no effect.
  • Inhibition was linked to transcriptional suppression of IL-1beta within 2 hours, and chloroquine abolished this effect.

Conclusions:

  • Specific ISS-ODN classes, particularly class B, can inhibit elevated TNF-alpha and IL-1beta production in inflamed human colonic mucosa.
  • The therapeutic effects of ISS-ODNs are mediated through TLR-9 activation.
  • These findings highlight the potential therapeutic utility of ISS-ODNs for managing ulcerative colitis.

More Related Videos

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice08:37

Induction of Murine Intestinal Inflammation by Adoptive Transfer of Effector CD4+CD45RBhigh T Cells into Immunodeficient Mice

Published on: April 21, 2015

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
Inflammatory Bowel Disease II: Ulcerative Colitis01:20

Inflammatory Bowel Disease II: Ulcerative Colitis

Ulcerative colitis is a chronic inflammatory disorder of the colon characterized by continuous mucosal inflammation that typically begins in the rectum and extends proximally in a uniform pattern. Its pathogenesis involves a complex interplay of genetic predisposition, immune dysregulation, and environmental influences. These factors converge to impair the colon’s epithelial defenses and promote an exaggerated inflammatory response against luminal contents.Breakdown of the Mucosal BarrierA...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease I: Ulcerative Colitis01:27

Inflammatory Bowel Disease I: Ulcerative Colitis

Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...